Mechanisms of drug resistance in colon cancer and its therapeutic strategies

被引:300
作者
Hu, Tao [1 ]
Li, Zhen [2 ]
Gao, Chun-Ying [3 ]
Cho, Chi Hin [1 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China
[2] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA
[3] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
关键词
Colon cancer; Drug resistance; ATP-binding cassette transporters; Evasion of apoptosis; Autophagy; GROWTH-FACTOR-RECEPTOR; OVERCOMING MULTIDRUG-RESISTANCE; SYNTHETASE GENE-EXPRESSION; CETUXIMAB PLUS IRINOTECAN; TYROSINE-KINASE INHIBITOR; AUTOPHAGIC CELL-DEATH; COLORECTAL-CANCER; BREAST-CANCER; P-GP; PHASE-I;
D O I
10.3748/wjg.v22.i30.6876
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Drug resistance develops in nearly all patients with colon cancer, leading to a decrease in the therapeutic efficacies of anticancer agents. This review provides an up-to-date summary on over-expression of ATP-binding cassette (ABC) transporters and evasion of apoptosis, two representatives of transport-based and non-transport-based mechanisms of drug resistance, as well as their therapeutic strategies. Different ABC transporters were found to be up-regulated in colon cancer, which can facilitate the efflux of anticancer drugs out of cancer cells and decrease their therapeutic effects. Inhibition of ABC transporters by suppressing their protein expressions or co-administration of modulators has been proven as an effective approach to sensitize drug-resistant cancer cells to anticancer drugs in vitro. On the other hand, evasion of apoptosis observed in drug-resistant cancers also results in drug resistance to anticancer agents, especially to apoptosis inducers. Restoration of apoptotic signals by BH3 mimetics or epidermal growth factor receptor inhibitors and inhibition of cancer cell growth by alternative cell death pathways, such as autophagy, are effective means to treat such resistant cancer types. Given that the drug resistance mechanisms are different among colon cancer patients and may change even in a single patient at different stages, personalized and specific combination therapy is proposed to be more effective and safer for the reversal of drug resistance in clinics.
引用
收藏
页码:6876 / 6889
页数:14
相关论文
共 159 条
[1]   Flavonoid structure-activity studies identify 6-prenyichrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2 [J].
Ahmed-Belkacem, A ;
Pozza, A ;
Muñoz-Martínez, F ;
Bates, SE ;
Castanys, S ;
Gamarro, F ;
Di Pietro, A ;
Pérez-Victoria, JM .
CANCER RESEARCH, 2005, 65 (11) :4852-4860
[2]   Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors [J].
Ahmed-Belkacem, Abdelhakim ;
Macalou, Sira ;
Borrelli, Francesca ;
Capasso, Raffaele ;
Fattorusso, Ernesto ;
Taglialatela-Scafati, Orazio ;
Di Pietro, Attilio .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (08) :1933-1938
[3]   Conquering the complexity of p53 [J].
Attardi, LD ;
DePinho, RA .
NATURE GENETICS, 2004, 36 (01) :7-8
[4]  
Benhattar J, 1996, INT J CANCER, V69, P190, DOI 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO
[5]  
2-V
[6]  
BENSON AB, 1985, CANCER TREAT REP, V69, P795
[7]   NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells [J].
Bentires-Alj, M ;
Barbu, V ;
Fillet, M ;
Chariot, A ;
Relic, B ;
Jacobs, N ;
Gielen, J ;
Merville, MP ;
Bours, V .
ONCOGENE, 2003, 22 (01) :90-97
[8]   The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia [J].
Besbes, Samaher ;
Pocard, Marc ;
Mirshahi, Massoud ;
Billard, Christian .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 :32-36
[9]   BH3 Mimetics: Status of the Field and New Developments [J].
Billard, Christian .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) :1691-1700
[10]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365